Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura

Joan D. Beckman, Marian A. Rollins-Raval, Jay S. Raval, Yara A. Park, Marshall Mazepa, Alice Ma

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.

Original languageEnglish (US)
Pages (from-to)e270-e272
JournalAmerican journal of therapeutics
Volume25
Issue number2
DOIs
StatePublished - Mar 1 2018

Fingerprint Dive into the research topics of 'Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura'. Together they form a unique fingerprint.

Cite this